hot tech

Texas A&M University technology used to prevent outages and wildfires

Two researches at Texas A&M University have developed a diagnostic software for monitoring electrical equipment to prevent outages and even wildfires. Getty Images

The threat of wildfires is on most people's minds as Australia suffers from devastating, uncontrollable fires in its southeastern region. While Australia's fires are alleged to be caused by natural occurrences, some, like the California wildfires of late 2019, are caused by electrical malfunctions and sparks

Engineers at Texas A&M University have found a solution for preventing these electricity-caused wildfires — and the subsequently caused electrical outages — with their diagnostic software called Distribution Fault Anticipation, or DFA. The software can interpret variations in the electrical current on utility circuits — usually caused by issues with the equipment — that can cause outages or spark fires.

A Texas A&M research team — spearheaded by B. Don Russell, professor of electrical and computer engineering, and research professor Carl L. Benner — is behind the DFA software.

The technology has been tested at over a dozen utilities in Texas over the past six years, according to a news release, and now two Californian utility companies — Pacific Gas & Electric and Southern California Edison — will be testing DFA. In 2018, a state law from the California Public Utilities Commission began requiring utilities to submit Wildfire Mitigation Plans, per the release.

Up next: The researchers are preparing to test the software in Australia and New Zealand.

DFA's specific algorithms are based on and refined through 15 years of research. Russell and Benner liken DFA to the diagnostic tools cars use, and, comparatively, the utilities industry is way behind the times.

"Utility systems operate today like my 1950s Chevy," Russell says in the release. "They have some fuses and breakers and things, but they really don't have anything diagnostic. They don't have that computer under the hood telling them what's about to go wrong."

B. Don Russell, professor of electrical and computer engineering, led the research at A&M. Photo via A&M

Normal wear and tear on electrical equipment is inevitable, but it's hard for inspectors to visually see this damage. Until this DFA software, utilities had no choice but to react to failures or outages, rather than put money into prevention. The software allows for these companies to better see what could potentially cause issues. And, now with the ability to factor in dry conditions and weather, the software can even predict potential wildfires.

"Power is being turned off with nothing known to be wrong with a given circuit," Russell says in the release. "Utilities need a crystal ball, something telling them which circuit is going to start a fire tomorrow because it is already unhealthy. We are kind of that crystal ball."

DFA has the potential to prevent outages and devastation caused by wildfires, and it also is a huge economic solution for utilities companies — especially the ones reeling from the recent fires in California.

Pacific Gas & Electric, which is testing nine DFA devices, is the state's largest utility company and recently filed for bankruptcy due to a near $100 billion required from settlements following recent fires. By comparison, a DFA device costs only $15,000, according to the release.

"DFA is a new tool, allowing utilities to transform their operating procedures to find and fix problems before catastrophic failures." Russell says in the release. "Utilities operators need real time situational awareness of the health of their circuits…..DFA does that."

Trending News

Building Houston

 
 

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Trending News